LNLusiné Nazaretyan

Lusiné Nazaretyan

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Lusiné Nazaretyan has a total of 6 co-authors. Here are the top co-authors by number of shared publications:

  • Martin Kircher

    Berlin Institute of Health at Charité – Universitätsmedizin Berlin, Berlin, Germany

    5 shared publications
  • Max Schubach

    Berlin Institute of Health at Charité – Universitätsmedizin Berlin, Berlin, Germany

    3 shared publications
  • Philipp Rentzsch

    Science for Life Laboratory, Department of Gene Technology, KTH Royal Institute of Technology

    2 shared publications
  • Martin Kircher

    Exploratory Diagnostic Sciences, Berlin Institute of Health at Charité - Universitätsmedizin Berlin, Berlin 10117, Germany; Institute of Human Genetics, University Hospital Schleswig-Holstein, University of Lübeck, Lübeck 23562, Germany

    1 shared publication
  • Sebastian Röner

    Computational Medicine, Medical and Health Data Sciences, Berlin Institute of Health at Charité - Universitätsmedizin Berlin, Berlin, Germany

    1 shared publication
  • Thorben Maass

    Institute for Chemistry and Metabolomics, Centre for Structural and Cell Biology in Medicine, University of Lübeck, Lübeck, Germany

    1 shared publication

Latest Publications

  • Open Access

    Data biases in genomics

    by Lusine Nazaretyan, Martin Kircher


  • Open Access

    varCADD: large sets of standing genetic variation enable genome-wide pathogenicity prediction

    by Lusiné Nazaretyan, Philipp Rentzsch, Martin Kircher

    Background: Machine learning and artificial intelligence are increasingly being applied to identify phenotypically causal genetic variation. These data-driven methods require comprehensive training sets to deliver reliable results. However, large unbiased datasets for variant prioritization and effect predictions are rare as most of the available databases do not represent a broad ensemble of variant effects and are often biased towards the protein-coding genome, or even towards few well-studied genes. Methods: To overcome these issues, we propose several alternative training sets derived from subsets of human standing variation. Specifically, we use variants identified from whole-genome sequences of 71,156 individuals contained in gnomAD v3.0 and approximate the benign set with frequent standing variation and the deleterious set with rare or singleton variation. We apply the Combined Annotation Dependent Depletion framework (CADD) and train several alternative models using CADD v1.6. Results: Using the NCBI ClinVar validation set, we demonstrate that the alternative models have state-of-the-art accuracy, globally on par with deleteriousness scores of CADD v1.6 and v1.7, but also outperforming them in certain genomic regions. Being larger than conventional training datasets, including the evolutionary-derived training dataset of about 30 million variants in CADD, standing variation datasets cover a broader range of genomic regions and rare instances of the applied annotations. For example, they cover more recent evolutionary changes common in gene regulatory regions, which are more challenging to assess with conventional tools. Conclusions: Standing variation allows us to directly train state-of-the-art models for genome-wide variant prioritization or to augment evolutionary-derived variants in training. The proposed datasets have several advantages, like being substantially larger and potentially less biased. Datasets derived from standing variation represent natural allelic changes in the human genome and do not require extensive simulations and adaptations to annotations of evolutionary-derived sequence alterations used for CADD training. We provide datasets as well as trained models to the community for further development and application.


  • Open Access

    varCADD: large sets of standing genetic variation enable genome-wide pathogenicity prediction

    by Lusiné Nazaretyan, Philipp Rentzsch, Martin Kircher

    Machine learning and artificial intelligence are increasingly being applied to identify phenotypically causal genetic variation. These data-driven methods require comprehensive training sets to deliver reliable results. However, large unbiased datasets for variant prioritization and effect predictions are rare as most of the available databases do not represent a broad ensemble of variant effects and are often biased towards protein-coding genome, or even towards few well-studied genes. To overcome these issues, we propose several alternative training sets derived from subsets of human standing variation. Specifically, we use variants identified from whole-genome sequences of 71,156 individuals contained in gnomAD v3.0 and approximate the benign set with frequent and the deleterious set with rare standing variation. We apply the Combined Annotation Dependent Depletion framework (CADD) and train several alternative models using CADD v1.6. Using the NCBI ClinVar validation set, we demonstrate that the alternative models have state-of-the art accuracy, outperforming the widely used pathogenicity score CADD v1.6 in certain genomic regions. Being larger than conventional databases, including the evolutionary-derived training dataset of about 30 million variants in CADD, standing variation datasets cover a broader range of genomic regions and rare instances of the applied annotations. For example, they cover more recent evolutionary changes common in gene regulatory regions, which are more challenging to assess with conventional tools. Finally, datasets derived from standing variation better represent allelic changes in the human genome and do not require extensive simulations and adaptations to annotations of the evolutionary-derived sequence alterations used for CADD training. We provide datasets as well as trained models to the community for further development and application. Suggestion for a Graphical Author‘s Summary: Here, we are presenting the varCADD approach for predicting variant deleteriousness. Throughout time, pathogenic allelic changes are selected against by purifying selection, while neutral or beneficial changes can be passed along to next generations. Consequently, the frequencies of pathogenic variants are decreasing, beneficial alleles are increasing and frequencies of neutral variants are subject to drift. For that, allele frequencies in standing variation can be used as a proxy for their deleteriousness. To train a machine learning model for variant prioritization, frequent variants from gnomAD 3.0 were used as proxy-benign set and rare variants as proxy-deleterious set. The resulting training set exceeds excisting data sets in their size and allows for genome-wide coverage of molecular effects. The training set was annotated with sequence conservation, epigenetic, sequence-based and other features using the CADD v1.6 framework, after which a logistic regression model was trained. The output of the model can be interpreted as a probability for a variant to have a deleterious effect on genetic function.


  • Top Cited Papers
    Open Access

    CADD v1.7: using protein language models, regulatory CNNs and other nucleotide-level scores to improve genome-wide variant predictions

    by Max Schubach, Thorben Maass, Lusiné Nazaretyan, Sebastian Röner, Martin Kircher

    Machine Learning-based scoring and classification of genetic variants aids the assessment of clinical findings and is employed to prioritize variants in diverse genetic studies and analyses. Combined Annotation-Dependent Depletion (CADD) is one of the first methods for the genome-wide prioritization of variants across different molecular functions and has been continuously developed and improved since its original publication. Here, we present our most recent release, CADD v1.7. We explored and integrated new annotation features, among them state-of-the-art protein language model scores (Meta ESM-1v), regulatory variant effect predictions (from sequence-based convolutional neural networks) and sequence conservation scores (Zoonomia). We evaluated the new version on data sets derived from ClinVar, ExAC/gnomAD and 1000 Genomes variants. For coding effects, we tested CADD on 31 Deep Mutational Scanning (DMS) data sets from ProteinGym and, for regulatory effect prediction, we used saturation mutagenesis reporter assay data of promoter and enhancer sequences. The inclusion of new features further improved the overall performance of CADD. As with previous releases, all data sets, genome-wide CADD v1.7 scores, scripts for on-site scoring and an easy-to-use webserver are readily provided via https://cadd.bihealth.org/ or https://cadd.gs.washington.edu/ to the community.


  • Open Access

    The Regulatory Mendelian Mutation score for GRCh38

    by Max Schubach, Lusiné Nazaretyan, Martin Kircher

    Background: Genome sequencing efforts for individuals with rare Mendelian disease have increased the research focus on the noncoding genome and the clinical need for methods that prioritize potentially disease causal noncoding variants. Some tools for assessment of variant pathogenicity as well as annotations are not available for the current human genome build (GRCh38), for which the adoption in databases, software, and pipelines was slow. Results: Here, we present an updated version of the Regulatory Mendelian Mutation (ReMM) score, retrained on features and variants derived from the GRCh38 genome build. Like its GRCh37 version, it achieves good performance on its highly imbalanced data. To improve accessibility and provide users with a toolbox to score their variant files and look up scores in the genome, we developed a website and API for easy score lookup. Conclusions: Scores of the GRCh38 genome build are highly correlated to the prior release with a performance increase due to the better coverage of features. For prioritization of noncoding mutations in imbalanced datasets, the ReMM score performed much better than other variation scores. Prescored whole-genome files of GRCh37 and GRCh38 genome builds are cited in the article and the website; UCSC genome browser tracks, and an API are available at https://remm.bihealth.org.


  • Open Access

    The Regulatory Mendelian Mutation score for GRCh38

    by Lusiné Nazaretyan, Martin Kircher, Max Schubach

    Motivation Various genome sequencing efforts for individuals with rare Mendelian disease have increased the research focus on the non-coding genome and the clinical need for methods that prioritize potentially disease causal non-coding variants. Some methods and annotations are not available for the current human genome build (GRCh38), for which the adoption in databases, software and pipelines was slow. Results Here, we present an updated version of the Regulatory Mendelian Mutation (ReMM) score, re-trained on features and variants derived from the GRCh38 genome build. Like its GRCh37 version, it achieves good performance on its highly imbalanced data. To improve accessibility and provide users with a toolbox to score their variant files and lookup scores in the genome, we developed a website and API for easy score lookup. Availability and Implementation Pre-scored whole genome files of GRCh37 and GRCh38 genome builds are available on Zenodo https://doi.org/10.5281/zenodo.6138102. The website and API are available at https://remm.bihealth.org.